Skip to main content
    D

    Dyne Therapeutics Inc (DYN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $16.70
    -0.46 (-2.68%)

    Market Cap: $3.22B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Dyne Therapeutics Inc (DYN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    Dyne Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$446.21M, operating cash flow was -$403.21M and free cash flow was -$423.92M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$193.55M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $468.18M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0-100.0%N/AN/AN/A
    Dec 2017$506.00M-63.0%-479.4%-81.4%15.0%
    Dec 2016$1.37BN/A-67.0%-46.9%-90.8%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$0$0$0$0$0$0$0$0$506.00M$1.37B
    Cost of revenue$0$0$0$0$0$0$0$24.00K$2.93B$2.28B
    Gross profit$0$0$0$0$0$0$0-$24.00K-$2.43B-$915.00M
    Research and development$398.33M$281.41M$210.76M$142.76M$121.31M$45.20M$11.04M$4.28M$0$0
    Operating income-$468.18M-$343.89M-$242.16M-$170.96M-$150.03M-$58.65M-$13.83M-$4.79M-$412.00M-$640.00M
    Net income-$446.21M-$317.42M-$235.94M-$168.10M-$149.29M-$59.44M-$14.86M-$4.81M$76.00M-$1.24B
    EBITDAN/AN/AN/A-$168.06M-$146.37M-$57.42MN/A-$4.79M$949.00M$106.00M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$1.57M$0$0$0$3.79M
    Gross profit$0$0$0-$521.00K$0$0$0$786.00K$0$0$0$3.22M
    Operating income-$197.07M-$181.66M-$125.28M-$116.13M-$113.89M-$115.79M-$122.37M-$97.20M-$105.57M-$71.96M-$69.16M-$67.69M
    Net income-$193.55M-$178.56M-$120.85M-$111.95M-$108.04M-$110.86M-$115.36M-$89.54M-$97.13M-$65.10M-$65.65M-$66.64M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $153.92M by $739.45M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$1.19B$691.23M$165.08M$306.32M$425.66M$353.33M$16.44M$8.27M$11.77B$13.05B
    Current assets$1.13B$659.28M$129.38M$265.59M$382.39M$349.09M$14.76M$8.16M$1.52B$2.99B
    Cash and equivalents$893.37M$435.45M$121.63M$172.15M$200.82M$300.85M$14.63M$8.12M$365.00M$1.78B
    Total liabilities$214.83M$61.40M$73.79M$53.96M$57.47M$10.97M$2.40M$13.15M$9.87B$11.01B
    Short-term debt$5.00M$4.85M$4.72M$4.61M$3.89MN/AN/AN/A$105.00M$201.00M
    Long-term debt$148.92M$0N/AN/AN/AN/AN/AN/AN/AN/A
    Shareholder equity$972.13M$629.84M$91.29M$252.36M$368.20M$342.37M$14.04M-$4.88M$1.90B$2.04B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$1.23B$994.01M$1.08B$1.19B$867.06M$728.99M$721.07M$691.23M$768.84M$825.88M$522.28M$165.08M
    Total liabilities$303.87M$291.86M$214.90M$214.83M$175.28M$157.55M$52.10M$61.40M$63.30M$50.69M$44.22M$73.79M
    Cash and equivalents$913.20M$676.11M$753.10M$893.37M$573.61M$485.04M$472.25M$435.45M$532.16M$608.20M$272.04M$121.63M
    Shareholder equity$930.93M$702.15M$865.05M$972.13M$691.78M$571.45M$668.97M$629.84M$705.54M$775.19M$478.06M$91.29M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$403.21M-$292.37M-$188.16M-$153.65M-$119.56M-$46.51M-$11.83M-$4.16M$585.00M$676.00M
    Capital expenditures$20.71M$2.38M$729.00K$3.07M$3.62M$1.16M$1.65M$134.00K$224.00M$326.00M
    Free cash flow-$423.92M-$294.75M-$188.89M-$156.71M-$123.18M-$47.67M-$13.48M-$4.30M$361.00M$350.00M
    Dividends paidN/AN/AN/AN/AN/AN/AN/AN/A$22.00M$22.00M
    Investing cash flow-$28.75M-$204.08M$83.31M$87.20M-$137.89M-$45.66M-$1.65M-$134.00K-$2.76B-$2.15B
    Financing cash flow$890.31M$809.89M$54.32M$37.39M$157.82M$380.69M$19.99M$12.42M-$1.30B$2.74B
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$177.49M-$130.29M-$144.92M-$111.83M-$90.78M-$94.70M-$105.89M-$84.33M-$74.63M-$54.87M-$78.54M-$35.01M
    Capital expenditures$2.01M$1.51M$221.00K$484.00K$19.18M$60.00K$981.00K$1.07M$253.00K$857.00K$191.00K$82.00K
    Free cash flow-$179.50M-$131.80M-$145.14M-$112.32M-$109.96M-$94.76M-$106.87M-$85.41M-$74.88M-$55.73M-$78.73M-$35.09M
    Last 12 quarters

    Frequently Asked Questions About DYN

    What is Dyne Therapeutics' annual revenue?

    Dyne Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Dyne Therapeutics profitable?

    No. Dyne Therapeutics reported net income of -$446.21M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does DYN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$403.21M minus capital expenditures of $20.71M produced free cash flow of -$423.92M.

    How much debt does Dyne Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $148.92M, short-term debt of $5.00M and cash and equivalents of $893.37M.